Innovative
Monoclonal Antibodies
Against Small Molecules
& Transmembrane Proteins

Therapeutic blocking C3aR - GPCR anaphylatoxin receptor - antibodies

hC3aR expression on the immunocompetent rat cell line

In black: non transfected rat cell line with a mean fluorescence of 4400
In red: stably transfected rat cell line with a mean fluorescence of 563000
Labelling: anti hC3ar Biolegend + GAM AF488

Affinity comparison between BioLegend anti-C3aR and SYnAbs LO-C3aR on U2O

In blue: SynAbs anti-C3aR antibody
In red: BioLegend anti-C3aR antibody
Labelling: Biolegend or SynC3aR+ GAM AF647

Blocking capacity of SynC3aR on C3a binding on

In blue: C3a AF647 50 ng/ml with mean fluorescence 66000
In red: C3a AF647 50 ng/ml + Synabs C3aR 833 ng/ml with mean Fluorescence 8800
In green: CCL1 AF647 50 ng/ml with mean fluorescence 1800

Inhibition curve of C3a-AF647 at various concentrations binding on USO2-C3aR

Maximum mean fluorescence (without SynC3aR) was 66000.
The maximal inhibition is reached, mean fluorescence 8800 at [SynC3aR]= 833 ng/ml,
The minimal labelling ( i.e; with CCL1-AF487) is at mean fluorescence = 1800.
At [SynC3aR]= 833 ng/ml, the inhibition rate is 89%

Do you want to know more about SYnAbs therapeutic blocking anti-human C3aR and test its potential as immune checkpoint inhibitor?